Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)

Archive ouverte

Valgimigli, Marco | Garcia-Garcia, Hector | Vrijens, Bernard | Vranckx, Pascal | Mcfadden, Eugène | Costa, Francesco | Pieper, Karen | Vock, David | Zhang, Min | van Es, Gerrit-Anne | Tricoci, Pierluigi | Baber, Usman | Steg, Gabriel | Montalescot, Gilles | Angiolillo, Dominick | Serruys, Patrick | Farb, Andrew | Windecker, Stephan | Kastrati, Adnan | Colombo, Antonio | Feres, Fausto | Jüni, Peter | Stone, Gregg | Bhatt, Deepak | Mehran, Roxana | Tijssen, Jan

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Abstract Non-adherence has been well recognized for years to be a common issue that significantly impacts clinical outcomes and health care costs. Medication adherence is remarkably low even in the controlled environment of clinical trials where it has potentially complex major implications. Collection of non-adherence data diverge markedly among cardiovascular randomized trials and, even where collected, is rarely incorporated in the statistical analysis to test the consistency of the primary endpoint(s). The imprecision introduced by the inconsistent assessment of non-adherence in clinical trials might confound the estimate of the calculated efficacy of the study drug. Hence, clinical trials may not accurately answer the scientific question posed by regulators, who seek an accurate estimate of the true efficacy and safety of treatment, or the question posed by payers, who want a reliable estimate of the effectiveness of treatment in the marketplace after approval. The Non-adherence Academic Research Consortium is a collaboration among leading academic research organizations, representatives from the U.S. Food and Drug Administration and physician-scientists from the USA and Europe. One in-person meeting was held in Madrid, Spain, culminating in a document describing consensus recommendations for reporting, collecting, and analysing adherence endpoints across clinical trials. The adoption of these recommendations will afford robustness and consistency in the comparative safety and effectiveness evaluation of investigational drugs from early development to post-marketing approval studies. These principles may be useful for regulatory assessment, as well as for monitoring local and regional outcomes to guide quality improvement initiatives.

Consulter en ligne

Suggestions

Du même auteur

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Archive ouverte | Capodanno, Davide | CCSD

International audience

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Archive ouverte | Gragnano, Felice | CCSD

International audience. Background In the GLOBAL LEADERS trial, ticagrelor monotherapy beyond 1 month compared with standard antiplatelet regimens after coronary stent implantation did not improve outcomes at intent...

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

Archive ouverte | Capodanno, Davide | CCSD

International audience

Chargement des enrichissements...